

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

208085Orig1s000

<i>Trade Name:</i>	Hydrocodone bitartrate and Guaifenesin, 5mg/400mg Tablets
<i>Generic or Established:</i>	Hydrocodone bitartrate and Guaifenesin
<i>Sponsor:</i>	ECI Pharmaceuticals, LLC
<i>Approval Date:</i>	April 25, 2018
<i>Indication:</i>	For the symptomatic relief of cough and to loosen mucus associated with the common cold in patients 18 years of age and older.

CENTER FOR DRUG EVALUATION AND RESEARCH

208085Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) • Summary Review • Office Director • Cross Discipline Team Leader • Clinical • Non-Clinical • Statistical • Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

208085Orig1s000

APPROVAL LETTER



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 208085

NDA APPROVAL

ECI Pharmaceuticals, LLC
5311 N.W. 35th Terrace
Fort Lauderdale, FL 33309

Attention: Himanshu Sud
Regulatory Agent

Dear Mr. Sud:

Please refer to your New Drug Application (NDA) dated April 13, 2016, received April 13, 2016, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Hydrocodone bitartrate and Guaifenesin, 5mg/400mg Tablets.

We also refer to our approval letter dated April 24, 2018 which contained the following error: the carton and container label included a proprietary name that had not been granted by the Agency.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain April 24, 2018, the date of the original approval letter.

We acknowledge receipt of your amendment dated October 30, 2017, which constituted a complete response to our February 13, 2017, action letter.

This new drug application provides for the use of Hydrocodone Bitartrate and Guaifenesin, 5mg/400mg Tablets for the symptomatic relief of cough and to loosen mucus associated with the common cold in patients 18 years of age and older.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information and text for the Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*,

available at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 208085.**” Approval of this submission by FDA is not required before the labeling is used.

PROPRIETARY NAME

If you intend to have a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the guidance for industry *Contents of a Complete Submission for the Evaluation of Proprietary Names*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075068.pdf> and “PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2008 through 2012”.)

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study(ies) requirement for this application because evidence strongly suggests the drug product would be ineffective and unsafe in all pediatric age groups. On September 11, 2017, the Pediatric Advisory Committee (PAC), met to review the use of prescription opioid products containing hydrocodone or codeine for the treatment of cough in pediatric patients. The committee determined that the benefit/risk assessment of prescription opioid cough products is not favorable because of limited benefit and issues related to safety of use of these products in children.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the prescribing information, Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the prescribing information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call LeAnn Brodhead, Regulatory Project Manager, at (240) 402-2605.

Sincerely,

{See appended electronic signature page}

Lydia Gilbert-McClain, M.D.
Deputy Director
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II

Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LEANN D BRODHEAD
04/25/2018

LYDIA I GILBERT MCCLAIN
04/25/2018